{
    "root": "3001f737-a4db-b824-e063-6294a90a784e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tazarotene",
    "value": "20250310",
    "ingredients": [
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH"
        },
        {
            "name": "CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED)",
            "code": "71DD5V995L"
        },
        {
            "name": "CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED)",
            "code": "HHT01ZNK31"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K"
        },
        {
            "name": "MEDIUM-CHAIN TRIGLYCERIDES",
            "code": "C9H2L21V7U"
        },
        {
            "name": "MINERAL OIL",
            "code": "T5L8T28FGP"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "SODIUM THIOSULFATE",
            "code": "HX1032V43M"
        },
        {
            "name": "SORBITAN MONOOLEATE",
            "code": "06XEA2VD56"
        },
        {
            "name": "TAZAROTENE",
            "code": "81BDR9Y8PS"
        }
    ],
    "indications": "tazarotene cream 0.05 % 0.1 % retinoid indicated topical treatment plaque psoriasis . ( 1.1 ) tazarotene cream 0.1 % indicated topical treatment acne vulgaris . ( 1.2 )",
    "contraindications": "apply thin layer tazarotene cream affected area daily evening . ( 2.1 , 2.2 ) ophthalmic , oral , intravaginal . ( 2.2 ) contact eyes occurs , rinse thoroughly water . ( 2.2 )",
    "warningsAndPrecautions": "tazarotene cream white off-white cream available concentrations 0.05 % 0.1 % . supplied collapsible aluminum tube tamper-evident aluminum membrane opening white polypropylene screw cap , 30 g 60 g sizes . tazarotene cream , 0.05 % tazarotene cream , 0.1 % 30 g ndc 0713-0765-31 ndc 0713-0670-31 60 g ndc 0713-0765-60 ndc 0713-0670-60 storage : store 20°c 25°c ( 68°f 77°f ) . excursions permitted -5°c 30°c ( 23°f 86°f ) .",
    "adverseReactions": "tazarotene cream contraindicated : pregnancy . retinoids may cause fetal harm administered pregnant female [ ( 5.1 ) , ( 8.1 , 8.3 ) ] . individuals known hypersensitivity components [ ( 5.2 ) ] .",
    "indications_original": "Tazarotene cream 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) Tazarotene cream 0.1% is indicated for the topical treatment of acne vulgaris. ( 1.2 )",
    "contraindications_original": "Apply a thin layer of tazarotene cream only to the affected area once daily in the evening. ( 2.1 , 2.2 ) Not for ophthalmic, oral, or intravaginal use. ( 2.2 ) If contact with eyes occurs, rinse thoroughly with water. ( 2.2 )",
    "warningsAndPrecautions_original": "Tazarotene cream is a white to off-white cream available in concentrations of 0.05% and 0.1%. It is supplied in a collapsible aluminum tube with a tamper-evident aluminum membrane over the opening and a white polypropylene screw cap, in 30 g and 60 g sizes.\n                               Tazarotene Cream, 0.05%                   Tazarotene Cream, 0.1% \n    30 g       NDC 0713-0765-31                             NDC 0713-0670-31 \n    60 g       NDC 0713-0765-60                             NDC 0713-0670-60\n \n                  \n                  \n                     Storage: Store at 20°C to 25°C (68°F to 77°F). Excursions permitted from -5°C to 30°C (23°F to 86°F).",
    "adverseReactions_original": "Tazarotene cream is contraindicated in:\n                  \n                     Pregnancy. Retinoids may cause fetal harm when administered to a pregnant female\n  \n   [see Warnings and Precautions (\n   \n    5.1), Use in Specific Populations (\n   \n    8.1,\n   \n    8.3)]\n  \n   .\n \n  \n                     Individuals who have known hypersensitivity to any of its components\n  \n   [see Warnings and Precautions (\n   \n    5.2)]\n  \n   ."
}